{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:14Z","timestamp":1783577714601,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>We performed a systematic review and meta-analysis of the efficacy and safety of teriparatide and bisphosphonates in managing postmenopausal osteoporosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, EMBASE, Web of Science, and China National Knowledge Infrastructure were searched for relevant randomized controlled trials that were published before April 2018 and compared teriparatide and bisphosphonates in treating postmenopausal osteoporosis. Stata 12.0 was used for the meta-analysis. The pooled risk ratio (RR) or weighted mean difference and 95% confidence interval (CI) were calculated using a fixed effects or random effects meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 14 randomized controlled trials were included in this meta-analysis. The teriparatide group was associated with a lower total occurrence of vertebral fractures (RR\u200a=\u200a0.55, 95% CI: 0.40\u20130.77; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001) and nonvertebral fractures (RR\u200a=\u200a0.65, 95% CI: 0.46\u20130.90; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.009) than the bisphosphonate group. Moreover, compared with the bisphosphonate group, the teriparatide group had improved bone mineral density at the lumbar spine and femoral neck at the final follow-up (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). There was no significant difference between the teriparatide and bisphosphonate groups in terms of complications (RR\u200a=\u200a1.05, 95% CI: 0.90, 1.22, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.516).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Teriparatide significantly reduced the occurrence of vertebral and nonvertebral fractures in osteoporosis patients. More studies should focus on the quality of life of patients using these 2 drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000018964","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T20:26:52Z","timestamp":1586550412000},"page":"e18964","source":"Crossref","is-referenced-by-count":21,"title":["Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Guiyong","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, Suzhou Kowloon Hospital of Shanghai Jiangtong University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, SuZhou WuJiang Hospital of Integrated Traditional Chinese and Western Medicine, Suzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lu","sequence":"additional","affiliation":[{"name":"The Affiliated Wuxi No.2 People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Suzhou Kowloon Hospital of Shanghai Jiangtong University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Suzhou Kowloon Hospital of Shanghai Jiangtong University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Suzhou Kowloon Hospital of Shanghai Jiangtong University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Suzhou Kowloon Hospital of Shanghai Jiangtong University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Suzhou Kowloon Hospital of Shanghai Jiangtong University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,4]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00198-019-04890-2","article-title":"Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis","volume":"30","author":"Watts","year":"2019","journal-title":"Osteoporos Int"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2017.21640","article-title":"Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: evidence report and systematic review for the US preventive services task force","volume":"319","author":"Kahwati","year":"2018","journal-title":"JAMA"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1550-8579(04)80013-5","article-title":"Osteoporosis screening of postmenopausal women in the primary care setting: a case-based approach","volume":"1","author":"Edwards","year":"2004","journal-title":"Gend Med"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","article-title":"Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00198-018-4791-3","article-title":"A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk","volume":"30","author":"Nayak","year":"2019","journal-title":"Osteoporos Int"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1749-6632.2010.05666.x","article-title":"Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis","volume":"1205","author":"Lyritis","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis","volume":"120","author":"Diez-Perez","year":"2019","journal-title":"Bone"},{"key":"R8-20230915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083138","article-title":"Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses","volume":"8","author":"Panic","year":"2013","journal-title":"PLoS One"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"Int J Clin Pract"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2017","journal-title":"Lancet"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"Cr442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"key":"R20-20230915","first-page":"9350","article-title":"Effects of teriparatide and alendronate in women with postmenopausal osteoporosis","volume":"4","author":"Chen","year":"2017","journal-title":"J Clin Med Literature"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"R24-20230915","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014340","article-title":"A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis","volume":"98","author":"Horikawa","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40618-014-0152-z","article-title":"Treatment of post-menopausal osteoporosis: beyond bisphosphonates","volume":"38","author":"Ishtiaq","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.25011\/cim.v40i3.28394","article-title":"Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis","volume":"40","author":"Liu","year":"2017","journal-title":"Clin Invest Med"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","article-title":"Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis","volume":"66","author":"Yuan","year":"2019","journal-title":"Int J Surg"},{"key":"R28-20230915","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.RVW.18.00052","article-title":"Clinical application of teriparatide in fracture prevention: a systematic review","volume":"7","author":"Chen","year":"2019","journal-title":"JBJS Rev"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","article-title":"Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis","volume":"24","author":"Freemantle","year":"2013","journal-title":"Osteoporos Int"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trial","volume":"66","author":"Han","year":"2012","journal-title":"Int J Clin Pract"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:28:30Z","timestamp":1694816910000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018964"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018964","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}